Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Alessandro Santin MD
Date Terminated: 02/14/2020
To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of Nivolumab with objective tumor response in patients with persistent, recurrent or metastatic carcinoma of the cervix, and to determine the nature and degree of toxicity of nivolumab as assessed by CTCAE.
Patients with persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease progression. All patients must have measurable disease with at least one target lesion to assess response by RECIST 1.1. Patients must have had one, and only one, prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix. Chemotherapy administered concurrent with primary radiation, or adjuvant chemotherapy given following the completion of radiation therapy, is not counted as a systemic chemotherapy regimen.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.